主要观点总结
本文主要介绍了多则关于生物医药领域的资讯，包括Leveragen与Moderna合作推进新疗法、洛启生物完成近3亿元B轮融资、神济昌华完成近亿元Pre-A轮融资等。
关键观点总结
关键观点1: Leveragen与Moderna合作
两家公司达成多目标研究、期权和许可协议，Leveragen将利用单域抗体技术为Moderna选择的疗法目标生成优化绑定模块。
关键观点2: 洛启生物完成近3亿元B轮融资
洛启生物成功完成近2亿元人民币的B2轮融资，累计融资近3亿元人民币。募集资金将主要用于推进两款吸入抗体药物的临床II期研究。
关键观点3: 神济昌华完成近亿元Pre-A轮融资
神济昌华成功完成近亿元Pre-A轮融资，融资资金将主要用于其首个管线SNUG01的IND申报及其他管线产品的推进。
关键观点4: IDEAYA与百奥赛图签订协议
IDEAYA将获得百奥赛图的潜在“first-in-class”双特异性抗体偶联药物疗法的全球独家许可，潜在总额超过4亿美元。
关键观点5: 阿斯利康的ADC药物在英国受阻
由于药物价格问题，英国NICE拒绝推荐使用阿斯利康与第一三共联合开发的Enhertu。
关键观点6: FDA新药申请费用上涨
FDA宣布，对于提交新药和生物制剂申请的公司，申请费用将在未来几年内上涨。
关键观点7: 药明巨诺任命新总裁
药明巨诺宣布任命刘敏为新总裁及执行董事，他之前在信达生物担任首席商务官。
文章预览
1 Leveragen与Moderna达成合作，利用单域抗体技术推进新疗法 On July 30, 2024, Leveragen, Inc., a Boston-based early-stage biotech company developing next-generation genetic models for antibody discovery, announced today that it has entered a multi-target research, option and license agreement with Moderna, Inc. Under the agreement, Leveragen will employ its proprietary fully human single domain antibody discovery platform to generate a panel of optimized binding modules against therapeutic targets selected by Moderna. Moderna will have the option to secure exclusive rights for the subsequent development and commercialization of the therapeutic products.During this partnership, Leveragen will spearhead the discovery of single domain antibody sequences for various targets. If Moderna decides to exercise its commercial option, it will be responsible for further development and commercialization efforts. Leveragen is set to receive an undisclosed upfront payment and researc
………………………………
